These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31249994)

  • 1. Cellular Trafficking of Sn-2 Phosphatidylcholine Prodrugs Studied with Fluorescence Lifetime Imaging and Super-resolution Microscopy.
    Maji D; Lu J; Sarder P; Schmieder AH; Cui G; Yang X; Pan D; Lew MD; Achilefu S; Lanza GM
    Precis Nanomed; 2018 Jul; 1(2):128-145. PubMed ID: 31249994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimuli-responsive PEGylated prodrugs for targeted doxorubicin delivery.
    Xu M; Qian J; Liu X; Liu T; Wang H
    Mater Sci Eng C Mater Biol Appl; 2015 May; 50():341-7. PubMed ID: 25746279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rod-like cellulose nanocrystal/cis-aconityl-doxorubicin prodrug: A fluorescence-visible drug delivery system with enhanced cellular uptake and intracellular drug controlled release.
    Li N; Lu W; Yu J; Xiao Y; Liu S; Gan L; Huang J
    Mater Sci Eng C Mater Biol Appl; 2018 Oct; 91():179-189. PubMed ID: 30033244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β₃-targeted theranostic nanoparticles.
    Pan D; Schmieder AH; Wang K; Yang X; Senpan A; Cui G; Killgore K; Kim B; Allen JS; Zhang H; Caruthers SD; Shen B; Wickline SA; Lanza GM
    Theranostics; 2014; 4(6):565-78. PubMed ID: 24723979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin conjugated phospholipid prodrugs as smart nanomedicine platforms for cancer therapy.
    Wang H; Liu X; Wang Y; Chen Y; Jin Q; Ji J
    J Mater Chem B; 2015 Apr; 3(16):3297-3305. PubMed ID: 32262324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. pH/ROS dual-responsive supramolecular polypeptide prodrug nanomedicine based on host-guest recognition for cancer therapy.
    Ding Y; Wang C; Ma Y; Zhu L; Lu B; Wang Y; Wang J; Chen T; Dong CM; Yao Y
    Acta Biomater; 2022 Apr; 143():381-391. PubMed ID: 35272024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acid-activatable prodrug nanogels for efficient intracellular doxorubicin release.
    Zhan F; Chen W; Wang Z; Lu W; Cheng R; Deng C; Meng F; Liu H; Zhong Z
    Biomacromolecules; 2011 Oct; 12(10):3612-20. PubMed ID: 21905663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy.
    Shim N; Jeon SI; Yang S; Park JY; Jo M; Kim J; Choi J; Yun WS; Kim J; Lee Y; Shim MK; Kim Y; Kim K
    Biomaterials; 2022 Oct; 289():121806. PubMed ID: 36156411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted sialic acid-doxorubicin prodrugs for intracellular delivery and cancer treatment.
    Jayant S; Khandare JJ; Wang Y; Singh AP; Vorsa N; Minko T
    Pharm Res; 2007 Nov; 24(11):2120-30. PubMed ID: 17668297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zwitterionic shielded polymeric prodrug with folate-targeting and pH responsiveness for drug delivery.
    Li L; Song Y; He J; Zhang M; Liu J; Ni P
    J Mater Chem B; 2019 Feb; 7(5):786-795. PubMed ID: 32254853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular Activation of a Prostate Specific Antigen-Cleavable Doxorubicin Prodrug: A Key Feature Toward Prodrug-Nanomedicine Design.
    Pereira SGT; Hudoklin S; Kreft ME; Kostevsek N; Stuart MCA; Al-Jamal WT
    Mol Pharm; 2019 Apr; 16(4):1573-1585. PubMed ID: 30802065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A glutathione-responsive sulfur dioxide polymer prodrug as a nanocarrier for combating drug-resistance in cancer chemotherapy.
    Shen W; Liu W; Yang H; Zhang P; Xiao C; Chen X
    Biomaterials; 2018 Sep; 178():706-719. PubMed ID: 29433753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring the Cellular Delivery of Doxorubicin-Cu Complexes in Cells by Fluorescence Lifetime Imaging Microscopy.
    Peng Z; Nie K; Song Y; Liu H; Zhou Y; Yuan Y; Chen D; Peng X; Yan W; Song J; Qu J
    J Phys Chem A; 2020 May; 124(21):4235-4240. PubMed ID: 32364735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. pH-Sensitive PEGylated liposomes for delivery of an acidic dinitrobenzamide mustard prodrug: Pathways of internalization, cellular trafficking and cytotoxicity to cancer cells.
    Yang MM; Wilson WR; Wu Z
    Int J Pharm; 2017 Jan; 516(1-2):323-333. PubMed ID: 27871834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. pH-Responsive prodrug nanoparticles based on a sodium alginate derivative for selective co-release of doxorubicin and curcumin into tumor cells.
    Gao C; Tang F; Gong G; Zhang J; Hoi MPM; Lee SMY; Wang R
    Nanoscale; 2017 Aug; 9(34):12533-12542. PubMed ID: 28819666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymeric prodrug microspheres with tumor intracellular microenvironment bioreducible degradation, pH-triggered "off-on" fluorescence and drug release for precise imaging-guided diagnosis and chemotherapy.
    Pei M; Li G; Ma K; Li J; Wang Y; Liu P
    Colloids Surf B Biointerfaces; 2019 May; 177():313-320. PubMed ID: 30771583
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Dong Y; Du P; Liu P
    Int J Pharm; 2020 Oct; 588():119723. PubMed ID: 32755688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin/heparin composite nanoparticles for caspase-activated prodrug chemotherapy.
    Khaliq NU; Sandra FC; Park DY; Lee JY; Oh KS; Kim D; Byun Y; Kim IS; Kwon IC; Kim SY; Yuk SH
    Biomaterials; 2016 Sep; 101():131-42. PubMed ID: 27286189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Cellular Uptake and Pharmacokinetic Characteristics of Doxorubicin-Valine Amide Prodrug.
    Park Y; Park JH; Park S; Lee SY; Cho KH; Kim DD; Shim WS; Yoon IS; Cho HJ; Maeng HJ
    Molecules; 2016 Sep; 21(10):. PubMed ID: 27669201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dextran-doxorubicin prodrug nanoparticles conjugated with CD147 monoclonal antibody for targeted drug delivery in hepatoma therapy.
    Tian H; Yu L; Zhang M; He J; Sun X; Ni P
    Colloids Surf B Biointerfaces; 2023 Aug; 228():113400. PubMed ID: 37331192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.